To our knowledge, this is the first attempt to characterize NFκB signaling in hypoxic breast cancer cells in response to a treatment modality, here in this case, radiotherapy and, further to delineate the modulation of altered signaling response to known anti-tumor phytochemicals. This evidence concerns the gene NFKB1 and breast carcinoma.